Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-5204
Fax+1 617-632-3408
Dr. Merriam is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2013
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2006
Certifications & Licensure
MA State Medical License 2013 - 2027
ME State Medical License 2022 - 2027
NH State Medical License 2023 - 2027
CT State Medical License 2022 - 2026
RI State Medical License 2006 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Feb 28
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Feb 08
Publications & Presentations
PubMed
- Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.Thierry Alcindor, David J Papke Jr, Vinayak Venkataraman, Michael J Wagner, Priscilla Merriam
JCO Precision Oncology. 2026-07-01 - Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.Alice P Chen, Christina L Rosenberger, Nancy Moore, Jared C Foster, Abdul Rafeh Naqash
Journal of Clinical Oncology. 2026-06-01 - A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.Gregory M Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian, Emanuele Mazzola
Clinical Cancer Research. 2026-06-01
Press Mentions
Dana-Farber Experts Present Innovative Cancer Studies at the 2025 AACR Annual MeetingApril 26th, 2025- Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
